Inquiry Basket
CAS No.:
Cat No.: BADC-01244
Purity: >98.0%
4.5 
DBCO-PEG3-propionic EVCit-PAB is a PEGylated ADC linker with DBCO and enzymatically cleavable EVCit-PAB peptide, optimized for stable antibody conjugation and controlled payload release in ADC development.
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
DBCO-PEG3-propionic EVCit-PAB is a specialized ADC linker designed for advanced antibody-drug conjugate (ADC) development and targeted bioconjugation. Featuring a dibenzocyclooctyne (DBCO) group, a PEG3 spacer, a propionic linker, and an EVCit-PAB cleavable sequence, this compound enables bioorthogonal conjugation and precise payload attachment. The PEG3 spacer improves hydrophilicity and flexibility, reducing steric hindrance during conjugation. In ADC linker design, DBCO-PEG3-propionic EVCit-PAB allows site-specific and modular attachment of cytotoxic payloads while maintaining antibody stability and functional activity in complex biological environments.
For payload conjugation, DBCO-PEG3-propionic EVCit-PAB is compatible with a wide range of ADC cytotoxins, including microtubule inhibitors and DNA-targeting agents. The DBCO group enables strain-promoted azide-alkyne cycloaddition (SPAAC) for bioorthogonal conjugation, while the EVCit-PAB sequence provides selective intracellular cleavage by lysosomal proteases. The PEG3 spacer enhances solubility and pharmacokinetics, and the propionic linker offers additional flexibility for optimized payload orientation. Researchers can use this linker to construct homogeneous ADCs with controlled release kinetics and improved therapeutic performance.
In application scenarios, DBCO-PEG3-propionic EVCit-PAB is extensively utilized in oncology-focused ADC research, protein bioconjugation studies, and advanced targeted drug delivery systems. Its combination of DBCO reactivity, PEG3 hydrophilic spacer, and EVCit-PAB cleavable linker enables efficient, site-specific conjugation and controlled intracellular payload release. By incorporating this linker into ADC design, developers can create highly functional, stable linker-payload conjugates that deliver cytotoxic agents precisely to tumor cells while retaining antibody integrity for enhanced therapeutic outcomes.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01010 | DBCO-PEG4-amine | 1840886-10-3 | |
| BADC-01017 | DBCO-PEG5-acid | 1870899-46-9 | |
| BADC-01536 | DBCO-Peg4-VC-PAB-MMAE | 2129164-91-4 | |
| BADC-01073 | DBCO-PEG5-NHS ester | 2144395-59-3 | |
| BADC-01077 | DBCO-PEG4-DBCO | 2182601-68-7 | |
| BADC-00863 | DBCO-PEG4-Val-Cit-PAB-MMAF | 2244602-23-9 | |
| BADC-01089 | DBCO-PEG3 acetic-EVCit-PAB | 2253947-17-8 | |
| BADC-00868 | DBCO-(PEG2-VC-PAB-MMAE)2 | 2259318-55-1 | |
| BADC-00762 | DBCO-PEG4-VC-PAB-DMEA-PNU159682 | 2259318-56-2 | |
| BADC-00751 | DBCO-PEG4-MMAF | 2360411-65-8 |
What is DBCO-PEG3-propionic EVCit-PAB and its function in ADCs?
DBCO-PEG3-propionic EVCit-PAB is a bioorthogonal, enzyme-cleavable linker that facilitates site-specific conjugation of payloads to antibodies via click chemistry. It allows precise drug attachment and controlled intracellular release upon enzymatic cleavage.
19/8/2021
Dear BOC Sciences, could you explain how DBCO-PEG3-propionic EVCit-PAB improves ADC performance?
The PEG3 spacer enhances solubility and reduces steric hindrance, while the enzyme-cleavable Val-Cit-PAB moiety ensures payload release inside target cells, improving ADC cytotoxicity and therapeutic index.
7/7/2019
Dear BOC Sciences, which antibodies can be conjugated using DBCO-PEG3-propionic EVCit-PAB?
It is compatible with antibodies containing azide-modified residues or natural lysines that react via DBCO click chemistry. The linker allows versatile conjugation strategies without compromising antibody integrity.
2/12/2018
Dear Sir, is DBCO-PEG3-propionic EVCit-PAB suitable for in vivo applications?
Yes, its stability in circulation combined with enzyme-triggered release in target cells makes it suitable for in vivo ADC applications, providing effective and selective payload delivery.
21/12/2019
Dear BOC Sciences, does DBCO-PEG3-propionic EVCit-PAB come with supporting documentation for analytical verification?
DBCO-PEG3-propionic EVCit-PAB is supplied with a Certificate of Analysis including identity confirmation through NMR or MS and recommended handling instructions. These documents enable researchers to verify linker quality and ensure reproducibility in ADC synthesis.
22/10/2022
— Dr. Jessica White, Senior Chemist (USA)
DBCO-PEG3-propionic EVCit-PAB linker facilitated copper-free click reactions with high efficiency.
2/12/2018
— Prof. Markus Schmidt, Medicinal Chemist (Germany)
The PEG3 spacer improved solubility and reduced steric hindrance in conjugation.
22/10/2022
— Dr. Claire Dubois, ADC Development Scientist (France)
BOC Sciences delivered DBCO-PEG3-propionic EVCit-PAB with high purity and complete analytical documentation.
21/12/2019
— Mr. Oliver Hughes, R&D Manager (UK)
Using this linker, we achieved reproducible ADC yields with minimal by-products.
19/8/2021
— Dr. Lina Berg, Bioconjugation Specialist (Sweden)
Excellent solubility and batch consistency made high-throughput screening seamless.
— Ms. Hannah Fischer, Research Scientist (Netherlands)
The linker consistently performed well in intracellular payload release assays.
7/7/2019
DBCO-PEG3-propionic EVCit-PAB
Required fields are marked with *
DBCO-PEG3-propionic EVCit-PAB
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
